Assembly Biosciences tops earnings, revenue forecasts
Drug developer Assembly Biosciences reported adjusted EPS of $0.53, beating expectations, while revenue exceeded analyst estimates for the quarter.
Assembly Biosciences Inc. reported adjusted earnings per share of $0.53 for the most recent quarter, surpassing the $0.00 estimate from analysts polled by Refinitiv. Revenue for the period totaled $12.4 million, exceeding the $11.2 million forecast.
The biopharmaceutical company, which focuses on gastrointestinal and liver diseases, attributed the better-than-expected results to higher-than-anticipated sales of its lead drug candidate. Assembly Biosciences has not provided full-year guidance, though management indicated continued progress in clinical trials and commercialization efforts.
Shares of Assembly Biosciences were indicated up nearly 8% in pre-market trading following the results. The company’s stock has gained approximately 15% over the past month, outperforming the broader biotech sector, which has seen modest gains amid regulatory and macroeconomic uncertainty.
Analysts at William Blair maintained an Outperform rating on the stock, citing the company’s strong execution and pipeline potential. Assembly Biosciences plans to release its next financial update alongside progress reports on its Phase 2b clinical trial for its lead asset in the second half of the year.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →